Use of histone modifiers to reprogram effector t cells
US-2021189337-A1 · Jun 24, 2021 · US
Expansion culture method for human-derived natural killer cells by using HDAC inhibitor
US12435310B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12435310-B2 |
| Application number | US-201917055678-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2019 |
| Priority date | May 16, 2018 |
| Publication date | Oct 7, 2025 |
| Grant date | Oct 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an expansion culture method for natural killer cells and, more particularly, to an expansion culture method for natural killer cells, wherein the cultured natural killer cells are treated with an HDAC inhibitor. According to the present invention, when natural killer cells are subjected to in vitro expansion culture, the cells can be restrained from undergoing cell death, resulting in a remarkable improvement in the viability and production yield of the cells. Thus, natural killer cells, which are needed for cell therapy, such as cancer therapy, etc., can be obtained effectively.
First claim
Opening claim text (preview).
The invention claimed is: 1. A culture method for expansion of natural killer cells, the method consisting of: (a) co-culturing natural killer cells with Jurkat cell line from Korea Cell Line Bank and EBV-LCL cell line from Korea Cell Line Bank, where each of the Jurkat cell line and the EBV-LCL cell line was irradiated with 100 Gy and at the natural killer cell lines: the Jurkat cell lines: the EBV-LCL cell lines ratio of 1:0.5:0.5 in hRPMI medium containing 10% FBS and 1% penicillin/streptomycin in presence of 500 U/ml of IL-2, for 5 to 15 days, and during the co-culturing, replacing the hRPMI medium with another hRPMI medium containing 500 U/ml of IL-2 once every 3 to 4 days; (b) treating the cultured natural killer cells with an HDAC (Histone deacetylase) inhibitor; and (c) additionally culturing the treated natural killer cells, wherein the natural killer cells are first treated with the HDAC inhibitor on day 6 of co-culturing, and then additionally treated with the HDAC inhibitor 1 to 3 times at intervals of 2 to 4 days, and wherein the HDAC inhibitor is Suberoylanilide-hydroxamic acid (SAHA) used at a concentration of 62.5 nM.
Assignees
Inventors
Classifications
Small molecules not provided for elsewhere · CPC title
Interleukin-2 (IL-2) · CPC title
- C12N5/0646Primary
Natural killers cells [NK], NKT cells · CPC title
Modulators of histone acetylation · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12435310B2 cover?
- The present invention relates to an expansion culture method for natural killer cells and, more particularly, to an expansion culture method for natural killer cells, wherein the cultured natural killer cells are treated with an HDAC inhibitor. According to the present invention, when natural killer cells are subjected to in vitro expansion culture, the cells can be restrained from undergoing c…
- Who is the assignee on this patent?
- Univ Korea Res & Bus Found
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0646. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).